Showing 6121-6140 of 8875 for: Cochrane Systematic Reviews Back
- Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy
Cochrane Systematic Reviews, 8-Jul-2016
Chagas disease-related cardiomyopathy is a major cause of morbidity and mortality in Latin America. Despite the substantial burden to the healthcare system, there is uncertainty regarding the efficacy and safety of pharmacological interventions for treati
- Pharmacological interventions for treating intrahepatic cholestasis of pregnancy
Cochrane Systematic Reviews, 27-Jul-2020
Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that can develop in pregnancy. It occurs when there is a build-up of bile acids in the maternal blood. It has been linked to adverse maternal and fetal/neonatal outcomes. As the pathophysiolo
- Pharmacological interventions for treatment‐resistant depression in adults
Cochrane Systematic Reviews, 17-Dec-2019
Although antidepressants are often a first-line treatment for adults with moderate to severe depression, many people do not respond adequately to medication, and are said to have treatment-resistant depression (TRD). Little evidence exists to inform the m
- Pharmacological interventions for unilateral spatial neglect after stroke
Cochrane Systematic Reviews, 6-Nov-2015
Unilateral spatial neglect (USN) is characterized by the inability to report or respond to people or objects presented on the side contralateral to the lesioned side of the brain and has been associated with poor functional outcomes and long stays in hosp
- Pharmacological interventions other than botulinum toxin for spasticity after stroke
Cochrane Systematic Reviews, 6-Oct-2016
The long-term risk of stroke increases with age, and stroke is a common cause of disability in the community. Spasticity is considered a significantly disabling impairment that develops in people who have had a stroke. The burden of care is higher in stro
- Pharmacological interventions to decrease blood loss and blood transfusion requirements for liver resection
Cochrane Systematic Reviews, 7-Oct-2009
Blood loss during liver resection is one of the most important factors affecting the peri-operative outcomes of patients undergoing liver resection.
- Pharmacological interventions versus no pharmacological intervention for ischaemia reperfusion injury in liver resection surgery performed under vascular control
Cochrane Systematic Reviews, 7-Oct-2009
Vascular occlusion to reduce blood loss is used during elective liver resection but results in significant ischaemia reperfusion injury. This, in turn, might lead to significant postoperative liver dysfunction and morbidity. Various pharmacological drugs
- Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3‐5D
Cochrane Systematic Reviews, 7-Jul-2021
Chronic kidney disease (CKD) is an independent risk factor for osteoporosis and is more prevalent among people with CKD than among people who do not have CKD. Although several drugs have been used to effectively treat osteoporosis in the general populatio
- Pharmacological management for agitation and aggression in people with acquired brain injury
Cochrane Systematic Reviews, 13-May-2008
Of the many psychiatric symptoms that may result from brain injury, agitation and/or aggression are often the most troublesome. It is therefore important to evaluate the efficacy of psychotropic medication used in its management.
- Pharmacological therapies for maintenance treatments of opium dependence
Cochrane Systematic Reviews, 29-Nov-2012
Pharmacologic therapies for maintenance treatment of heroin dependence have been used and studied widely. Systematic reviews have demonstrated the effectiveness of such therapies. Opium dependence is associated with less problems and impairments and is le
- Pharmacological therapies for management of opium withdrawal
Cochrane Systematic Reviews, 19-Jun-2018
Pharmacologic therapies for management of heroin withdrawal have been studied and reviewed widely. Opium dependence is generally associated with less severe dependence and milder withdrawal symptoms than heroin. The evidence on withdrawal management of he
- Pharmacological treatment for antipsychotic‐related constipation
Cochrane Systematic Reviews, 24-Jan-2017
Antipsychotic-related constipation is a common and serious adverse effect, especially for people taking clozapine. Clozapine has been shown to impede gastrointestinal motility, leading to constipation, and has been reported in up to 60% of patients receiv
- Pharmacological treatment for aphasia following stroke
Cochrane Systematic Reviews, 23-Oct-2001
Aphasia describes language impairment associated with a brain lesion.
- Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders
Cochrane Systematic Reviews, 26-Jun-2018
This is an update of the original Cochrane Review published in Issue 4, 2011.
- Pharmacological treatment for Buerger's disease
Cochrane Systematic Reviews, 4-May-2020
Buerger's disease (thromboangiitis obliterans) is a non-atherosclerotic, segmental inflammatory pathology that most commonly affects the small and medium sized arteries, veins, and nerves in the upper and lower extremities. The aetiology is unknown, but i
- Pharmacological treatment for central sleep apnoea in adults
Cochrane Systematic Reviews, 27-Feb-2023
The term central sleep apnoea (CSA) encompasses diverse clinical situations where a dysfunctional drive to breathe leads to recurrent respiratory events, namely apnoea (complete absence of ventilation) and hypopnoea sleep (insufficient ventilation) during
- Pharmacological treatment for continuous spike‐wave during slow wave sleep syndrome and Landau‐Kleffner Syndrome
Cochrane Systematic Reviews, 6-Nov-2020
Continuous spike-wave during slow wave sleep syndrome (CSWS) and Landau-Kleffner syndrome (LKS) are two epileptic encephalopathies that present with neurocognitive regression, aphasia, and clinical seizures, typically presenting in children around five ye
- Pharmacological treatment for depression during opioid agonist treatment for opioid dependence
Cochrane Systematic Reviews, 22-Jul-2010
Lifetime prevalence of depression in subjects with opioid dependence is higher than in the general population (44-54% versus 16%) and represents a risk factor for morbidity and mortality. For patients on opioid agonist treatment, current prevalence rates
- Pharmacological treatment for familial amyloid polyneuropathy
Cochrane Systematic Reviews, 20-Apr-2020
Disease-modifying pharmacological agents for transthyretin (TTR)-related familial amyloid polyneuropathy (FAP) have become available in the last decade, but evidence on their efficacy and safety is limited. This review focuses on disease-modifying pharmac
- Pharmacological treatment for Kleine‐Levin syndrome
Cochrane Systematic Reviews, 6-May-2016
This is an updated version of the original Cochrane review, published in 2009, Issue 2.
